There were 1,831 press releases posted in the last 24 hours and 465,950 in the last 365 days.

Threshold Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference

Company Presentation Scheduled for June 7, 2016 at 3:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold’s Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on June 7, 2016 at 3:30 p.m. Eastern Time.

To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the Company's web site at www.thresholdpharm.com. Please connect to the web site at least 15 minutes prior to the presentation to allow for any software download that may be necessary. An archived replay will be available for 30 days beginning 24 hours after the live presentation.

About Threshold Pharmaceuticals
Threshold is a clinical-stage biopharmaceutical company focused on the discovery and development of drugs and diagnostic agents targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit the Company's website.

Contact
Denise Powell
denise@redhousecomms.com
510.703.9491

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.